the aid library

LIST OPTIONS

Filter

422

Download (193)

View PDF (192)

Annex 3. Dosages of ARV drugs

World Health Organization (2019) C_WHO

Accessed: 19.10.2019

Download (160)

View PDF (232)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection - AIDSinfo

AIDSinfo (2019) C2

Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019 Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC)

Download (204)

View PDF (190)

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

AIDSinfo; CDC Centers for Disease Control and Prevention; National Institutes of Health; et al. (2019) C2

Downloaded from https://aidsinfo.nih.gov/guidelines on 11/27/2019 Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.

External Link

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank

M. Vitoriaa; N. Forda; P. Clayden; et al. Wolters Kluwer Health; World Health Organization (2017) C2

Review www.co-hivandaids.com Volume 12 􏰀 Number 4 􏰀 July 2017

Download (115)

View PDF (160)

HIV Pipeline 2018

i-base (2018) C2

htb supplement: 2018 Vol 19:(1) New drugs in development July 2018 www.i-Base.info

Considerations for introducing new antiretroviral drug formulations for children

World Health Organization WHO (2020) CC

Policy brief. July 2020

Key technical issues of herbal medicines with reference to interaction with other medicines

World Health Organization WHO (2020) C_WHO

External Link

Full prescribing information Fexinidazole tablets, for oral use

Drugs for Neglected Diseases initiative DNDi (2021) C1

Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati... more

Download (287)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Download (1629)

View PDF (1630)

5th Essential Drugs List and Standard Treatment Guidelines for Zimbabwe

Ministry of Health and Child Welfare, Zimbabwe (2006) C1

External Link

Checklist for Core Elements of Hospital Antibiotic Stewardship Programs
recommended

Centers for Disease Control and Prevention (CDC) (2014) C_CDC

The following checklist is a companion to Core Elements of Hospital Antibiotic Stewardship Programs. This checklist should be used to systematically assess key elements and actions to ensure optimal antibiotic prescribing and limit overuse and misuse of antibiotics in hospitals. CDC recommends that ... more

Download (594)

View PDF (1167)

Target Regimen Profiles for TB Treatment

World Health Organization WHO (2016) C_WHO

There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi... more

Download (647)

View PDF (699)

Sierra Leone: Guidelines for Conducting Clinical Trials of Medicinal Products and Vaccines

Pharmacy Board Sierra Leone (2014) C1

Download (218)

View PDF (258)

Checklist for Core Elements of Hospital Antibiotic Stewardship

Centers for Disease Control and Prevention CDC (2019) C_CDC

COVID-19: Chloroquine and hydroxychloroquine research

World Health Organization WHO (2020) C_WHO

This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing clinical tri... more

View PDF (808)

An evaluation of the prescribing patterns for under‑five patients at a Tertiary Paediatric Hospital in Sierra Leone

Cole CP, James PB, Kargbo AT (2015) CC

An evaluation of the prescribing patterns for under-five patients at a Tertiary Paediatric Hospital in Sierra Leone. J Basic Clin Pharma 2015;6:109-14.

Annex 3. Dosages of ARV drugs

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection - AIDSinfo

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank

HIV Pipeline 2018

Considerations for introducing new antiretroviral drug formulations for children

Key technical issues of herbal medicines with reference to interaction with other medicines

Full prescribing information Fexinidazole tablets, for oral use

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

5th Essential Drugs List and Standard Treatment Guidelines for Zimbabwe

Checklist for Core Elements of Hospital Antibiotic Stewardship Programs
recommended

Target Regimen Profiles for TB Treatment

Sierra Leone: Guidelines for Conducting Clinical Trials of Medicinal Products and Vaccines

Checklist for Core Elements of Hospital Antibiotic Stewardship

COVID-19: Chloroquine and hydroxychloroquine research

A Practical Guide to Antimicrobial Stewardship Program in Ethiopian Hospitals

Evaluation of drug promotional materials in a hospital setting in Nepal

Formulary of Narcotic Drugs and Psychotropic Substances for Ethiopia

An evaluation of the prescribing patterns for under‑five patients at a Tertiary Paediatric Hospital in Sierra Leone

Checklist for Core Elements of Hospital Antibiotic Stewardship Programs recommended

Checklist for Core Elements of Hospital Antibiotic Stewardship Programs
recommended